Back to search

National and Kapodistrian University of Athens

Studies on the bioavailability and pharmacokinetics of EGF-conjugates in breast and non-small cell lung cancer

Abstract

dc:description

Despite years of research, cancer still represents one of the most challenging and difficult diseases to treat. Extensive research has resulted in the evolution of cancer treatment based on relatively nonspecific cytotoxic agents towards more selective, mechanism-based therapeutics. Cancer chemotherapies were initially identified through screens for compounds that killed rapidly dividing cells. These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities, poor pharmacokinetic properties and frequently acquired resistance. Recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy. Non-small cell lung cancer (NSCLC) is characterized by high mortality rates, as it is responsible for approximately 85% of all lung cancers. Similarly, breast cancer (BrCa) is the second most commonly diagnosed cancer in Western Europe and the most frequent cause of death from cancer in women, accounting for 91.000 deaths per year. Molecular profiling of BrCa and NSCLC has indicated key proteins, which have been involved in signaling pathways that are commonly activated in many physiological responses such as growth factor receptor tyrosine kinases (RTKs). A widely known RTK with important role in the pathogenesis of human cancer is the epidermal growth factor receptor (EGFR). EGFR has been found to be overexpressed in more than 65% of NSCLCs cases. In breast cancer, approximately 18% of patients are EGFR positive, with 25% of these patients showing HER2 overexpression that has been related with poor prognosis and disease recurrence. The correlation of these two cancer types with EGFR presents an opportunity for the development of improved therapeutic approaches for targeted therapy of BrCa and NSCLC. The main scientific research aim of the current thesis was the evaluation of novel compounds based on two strategies. The first strategy was focused in the design and synthesis of peptide drug conjugates (PDCs) that target the epidermal growth factor receptor EGFR (HER1 for NSCLC and HER2 for BrCa) with primary aim of improving the overall antitumor activity. This was achieved by conjugating ligands that target the EGFR through appropriate linkers to anticancer drugs (Gemcitabine, Sunitinib) of varying therapeutic potential approved for the treatment of BrCa and NSCLC. The PDCs were evaluated in terms of physicochemical properties and in vitro effects. EGF-gemcitabine conjugates were studied in terms of cytotoxicity, in vitro stability and cellular and metabolite formation in different breast and non-small cell lung cancer cell lines. All of the conjugates (H1P1SG, H1P2SG and H2P1SG) tested displayed good antiproliferative activity. H1P2SG was the most potent among them especially, in the breast cancer cell line MDA-MB-231 (IC50=576 nM) compared to gemcitabine (IC50=489 nM). This conjugate also displayed good cellular uptake profile compared with gemcitabine in the NSCLC cancer cell line A549 thus representing a good candidate for further in vivo studies. EGF-sunitinib conjugates were studied in terms of cytotoxicity in different BrCa and NSCLC cell lines. The conjugates (H2P1SS and H2P1RSS) tested displayed good antiproliferative activity. H2P1SS was the most potent among them especially, in the breast cancer cell line HCC-1954 (IC50=18 nM) compared to sunitinib (IC50=14 nM), thus representing a good candidate for further in vitro and in vivo studies. SAP is a new linkable sunitinib analogue and has many advantages over the original molecule including improved solubility and enhanced pharmacokinetic parameters. In addition, experimental studies have shown that SAP retains cytotoxic and antiangiogenic properties of the parental molecule with increased tumor accumulation compared to sunitinib. SAP can provide access to targeting peptide-drug conjugates employing a series of cleavable linkers. Study of the model SAP compounds with cleavable disulphide (SAP-S-S-Py) or dipeptide linkers (i.e. Val-Cit) showed that release of SAP could be achieved in vivo in such a peptide-drug conjugate through the use of such cleavable linkers. A series of SAP conjugates with HER-1 and HER-2 targeting peptides were then synthesized. The second strategy was based on the design and synthesis of novel substituted purine isosters, as potential EGFR inhibitors. Novel substituted purine isosters, were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the NSCLC cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One lapatinib analogue, compound (23) displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23) was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib. The two novel therapeutic strategies developed in the current thesis will give the opportunity to a number of compounds to be used as alternative treatments via the targeting of EGFR leading to valuable insights associated with BrCa and NSCLC treatment and possibly improvement for the therapeutic options of BrCa and NSCLC patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Doukatas, Aris
  • Δουκατάς, Άρης

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • BY_NC
Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/47755

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Doukatas, Aris; Δουκατάς, Άρης. Studies on the bioavailability and pharmacokinetics of EGF-conjugates in breast and non-small cell lung cancer. National and Kapodistrian University of Athens, 2019. http://hdl.handle.net/10442/hedi/47755